Ado-trastuzumab emtansine: Avoiding side-effects of traditional HER2 positive breast cancer treatment. (October 2021)

• Record Type: Journal Article
• Authors: Turshudzhyan, Alla; Vredenburgh, James
• Is Part Of: Journal of oncology pharmacy practice. Volume 27:Number 7(2021)
• Page Start: 1770
• Page End: 1774
• Publication Date: 2021-10
• Subjects: HER2 -- breast cancer -- ado-trastuzumab emtansine; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155220985598
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: Approach to cancer treatment is dictated by guidelines based on clinical research. New research continuously changes what we consider to be first-line therapy for a given type of cancer. Treatment approach becomes more complex when patient's cultural beliefs have to be considered and incorporated into the therapy. Case report: We are presenting a case of a patient born and raised in the former Soviet Union, whose understanding of how cancer should be treated was considerably different from what we now deem to be first-line therapy. This patient was diagnosed with metastatic HER2 positive breast cancer. Management and outcome : Having reservations about first-line therapy, she wanted to consider surgery as well as other lines of therapy. Her medical team worked on finding an alternative treatment plan that would be in line with her goals of care. Patient's personal beliefs led her to choose a therapy that is currently a second-line: Ado-trastuzumab emtansine. She was able to achieve full remission. Discussion: Some recent studies discussed in this case showed that first-line therapies don't have significant progression free survival advantage when compared to the second-line therapy that our patient received. Ado-trastuzumab emtansine is a potent cytotoxic drug connected via a stable linker to the anti-HER2 antibody, trastuzumab. More studies need to be done to further investigate positive result presented in this case and whether this could be considered an alternative to current first-line therapy.